James Noble MA FCA, Chief Executive Officer

James Noble

James has over two decades of experience in biotechnology, having served on public and private boards of companies in the UK, the USA and Germany.

At the executive level, he served as CFO of British Biotech plc from 1990 to 1997, where he was responsible for raising over £300 million in equity capital from the UK, USA, Japan and continental Europe and for the simultaneous listing in London and on NASDAQ. James was the CEO of Avidex (the predecessor company of Adaptimmune) from 2000 and 2006 when the company was sold to MediGene AG, where James joined the supervisory board. James was responsible for the spin-outs of both Immunocore and Adaptimmune from MediGene in 2008 and served as CEO of both. In March 2014, James relinquished his position as CEO of Immunocore in order to focus exclusively as CEO of Adaptimmune, although he remains a non-executive director of Immunocore.

At the non-executive level, James has served on a number of boards including: Oxford Glycosciences plc, Curagen Inc, PowderJect Pharmaceuticals plc and was the founding chairman of Biovex. He is currently Deputy Chairman at GW Pharmaceuticals plc, a NASDAQ and AIM-listed biotech company.

Prior to his involvement in the biotech industry, James graduated from Oxford in 1980 and qualified as a chartered accountant with Price Waterhouse in 1983. He then spent seven years at Kleinwort Benson Limited, reaching Director in 1990.

Bent Jakobsen PhD, Chief Scientific Officer

Bent Jakobsen

Dr Jakobsen founded Avidex, the forerunner company to Adaptimmune and Immunocore, in March 1999 becoming full-time Chief Scientific Officer and Executive Board member in July 2000. Bent founded Avidex whilst he was at the Institute of Molecular Medicine (IMM) in Oxford, where he was head of the Immune Receptor Group from 1993 to July 2000. This group is recognised as one of the leading international laboratories in molecular immunology and is a world leader in recombinant immune receptor technology. Prior to this, he was a Senior Research Fellow of the Danish Natural Research Council, Aarhus, Denmark. This followed three years as a Post-doctoral researcher at the Laboratory of Molecular Biology of the Medical Research Council in Cambridge. Bent has been CSO of Adaptimmune since its inception as a spin-out of Avidex/MediGene in 2008 and is responsible for all aspects of its research programmes.

Helen Tayton-Martin PhD MBA, Chief Operating Officer

Helen Tayton-Martin

Helen Tayton-Martin is COO of Adaptimmune Ltd. With a PhD in molecular immunology and an MBA from London Business School, she has nearly 20 years of experience working within the Pharma, biotech and consulting environment in disciplines across preclinical and clinical development, strategic planning, due diligence and business development. Helen joined Adaptimmune from Avidex/MediGene Ltd. where she was responsible for commercial development of the soluble TCR programme in cancer and HIV therapy. Helen is responsible for all development and commercial activities, including business development and implemented Adaptimmune’s strategic partnership with GSK.

Gwen Binder-Scholl PhD, Executive Vice President Adaptimmune LLC

Gwen Binder-Scholl

Gwendolyn Binder-Scholl is responsible for driving all aspects of Adaptimmune LLC including its ongoing clinical trials in HIV and cancer and strategic development planning. She is a biochemistry and molecular biology graduate of Wells College, New York with a PhD in Cellular and Molecular Medicine from Johns Hopkins University, Baltimore. Gwen has extensive industry and academic experience in cellular and gene therapy translational research and development, joining Adaptimmune as a former Director of Translational Research Operations at the University of Pennsylvania and prior to that Director of Scientific Affairs at Virxsys Corporation.